Overview
PDS Biotech’s pipeline combines Versamune® technology with disease-specific antigens in both the development of cancer immunotherapies and infectious disease vaccines.
Product | Indication | Combination | PC | P1 | P2 | P3 | R | PARTNER(S) | |
---|---|---|---|---|---|---|---|---|---|
Infectious Disease | |||||||||
PDS0203 (SARS-CoV-2) |
Prevention of COVID-19 |
|
|
![]() |
|||||
|
|||||||||
PDS0201 (M-tuberculosis) |
Prevention of tuberculosis |
|
|
![]() |
|||||
|
|||||||||
PDS0202 (influenza) |
Universal prevention of influenza |
|
|
![]() |
|||||
|
|||||||||
PDS Biotech Funded ![]() |
Partner Co-Funded ![]() |